InvestorsHub Logo
Followers 0
Posts 181
Boards Moderated 0
Alias Born 09/03/2003

Re: tryz post# 28996

Friday, 07/21/2006 6:55:02 PM

Friday, July 21, 2006 6:55:02 PM

Post# of 203990
http://www.xechemnigeria.org/products.htm

The conversion of 1 US$ ~= 128 nigerian dollar per yahoo finance. SO Nicosan is selling for 18.75/24 for 250mg/350mg. Though it didn't say how many day supply and I assume its 30 days.

Copied from the website:
=========================================================
In July, 2002, Xechem acquired an exclusive, worldwide license to develop NICOSAN™ (HEMOXIN™ in the US) from the Nigerian government and, subsequently, received U.S. orphan drug status for HEMOXIN™ from the FDA in August, 2003. The product is made from four botanical species indigenous to Nigeria. NICOSAN™ is produced there today by Xechem. The Company expects to launch NICOSAN™ in Nigeria’s 4,000,000 SCD patient market, the world’s largest SCD market, in 2005. SCD, a devastating hereditary blood disorder characterized by acute painful crisis, organ damage, anemia and early death, affects over 80,000 African Americans in the U.S. alone. Based on published data and human experience, the Company believes the successful clinical development of HEMOXIN™ represents an unusually low risk. In phase II human studies in Nigeria, published in Phytomedecine, HEMOXIN™ was shown to be safe in all patients and effective in approximately 80% of patients. As published in the May 2003 issue of the British Journal of Hematology, Asakura and colleagues from Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania demonstrated the anti-sickling effects of HEMOXIN™ in transgenic mice. This lends significant credibility to the Nigerian human experience to initiate clinical trials in the U.S.
=========================================================

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.